falsefalse

Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 12

CARTITUDE-4 Subgroup Analysis: When Cilta-Cel Should Be Considered

, , ,

Panelists discuss how subgroup analyses of cilta-cel support its efficacy in high-risk cytogenetics and extramedullary disease, though bridging therapy and patient selection remain key for optimal outcomes.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Subgroup Analysis of Cilta-cel in High-Risk Myeloma
    Subgroup data from the CARTITUDE-4 study confirm that cilta-cel remains effective in patients with high-risk cytogenetics and extramedullary disease. While these groups typically have poor outcomes, cilta-cel provided notable improvements in progression-free survival.

    However, extramedullary disease continues to present challenges, with responses being less durable than in bone-only disease. The need for further innovation in this subgroup remains critical, even as outcomes improve with CAR T therapy.

    Clinicians are encouraged to initiate disease control with bridging regimens before CAR T infusion to optimize safety and efficacy. Early referral and preparation are essential for ensuring access and reducing attrition before CAR T administration.

    x